New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
07:04 EDTNEPT, ACSTAcasti Pharma announces resignation of CFO
Acasti Pharma (ACST) announces the resignation of Xavier Harland as CFO of Acasti with immediate effect. Effective immediately, the functions of CFO for Acasti will be assumed by André Godin, Interim president and CEO of Acasti, who is currently also CFO of Neptune Technologies and Bioressources (NEPT).
News For ACST;NEPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 21, 2014
08:08 EDTNEPTNeptune Technologies appoints Jim Hamilton as CEO
Subscribe for More Information
November 11, 2014
08:11 EDTACSTAcasti Pharma receives NASDAQ notification regarding minimum bid requirements
Acasti Pharma announces that on November 7 it received notification from the NASDAQ Listing Qualifications Department for failing to maintain a minimum bid price of $1.00 per share for the last 30 consecutive business days, as required by NASDAQ Listing Rule 5550(a)(2) – bid price. The NASDAQ notification has no immediate effect on the listing of the Corporation's shares. Under NASDAQ rule 5810(c)(3)(A) – compliance period, the corporation has 180 calendar days, or until May 6, 2015, to regain compliance. If at any time over this period the bid price of Acasti's shares closes at $1.00 per share or more for a minimum of ten consecutive business days, NASDAQ will provide written confirmation of compliance and the matter will be closed. If Acasti does not regain compliance within the initial 180-day period, but meets the continued listing requirements for market value of publicly held shares and all other initial listing standards for the NASDAQ Capital Market, except for the bid price requirement, the corporation may be eligible for an additional 180 calendar days to regain compliance. If the corporation is not granted additional time, then the securities will be subject to delisting, at which time the corporation may appeal the delisting determination to a NASDAQ Hearings Panel. The company intends to evaluate all available options to resolve the deficiency and regain compliance with the Minimum Bid Price Rule.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use